Remdesivir was found to be associated with faster clinical improvement in a largely non-white group of patients admitted to the hospital with COVID-19, reported a new study. A little over 80% of patients receiving remdesivir in the study identified as non-white.

A retrospective analysis of nearly 2,300 hospitalized COVID-19 patients in Baltimore and Washington, D.C. noted that the median time to clinical improvement was shorter among patients who were given remdesivir compared to those who were not given the drug (5 vs. 7 days, adjusted HR 1.47, 95% CI 1.22-1.79). There was no significant difference in 28-day mortality, though the trend favored remdesivir (7.7% vs. 14.0% in controls). The findings were published in JAMA Network Open… (Medpage Today)